No recommendation
No news or research item is a personal recommendation to deal. Hargreaves Lansdown may not share ShareCast's (powered by Digital Look) views.
(Sharecast News) - Proteome Sciences said on Monday that it had secured a further significant clinical contract linked to its target engagement and chemoproteomics platform.
See latest RNS on InvestegateThe AIM-traded company said it expected the contract to act as a precursor to a new clinical trial programme due to start later in 2026.
Executive chairman Christopher Pearce said momentum and growth in Proteome's chemoproteomics services was continuing this year, adding that the company had generated "considerable interest and attention" at the recent American Society for Mass Spectrometry meeting in San Diego.
At 1016 BST, shares in Proteome Sciences were up 9.27% at 1.65p.
Reporting by Josh White for Sharecast.com.
See latest RNS on Investegate
The value of investments can go down in value as well as up, so you could get back less than you invest. It is therefore important that you understand the risks and commitments. This website is not personal advice based on your circumstances. So you can make informed decisions for yourself we aim to provide you with the best information, best service and best prices. If you are unsure about the suitability of an investment please contact us for advice.